CORRIGENDUM

Corrigendum to “A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD” [Respir Med, 107 (2013) 560–569]

Edward M. Kerwin a,*, Catherine Scott-Wilson b, Lisa Sanford c, Stephen Rennard d, Alvar Agusti e, Neil Barnes f, Courtney Crim b

a Clinical Research Institute of Southern Oregon, 3860 Crater Lake Avenue, Medford, OR 97504, USA
b GlaxoSmithKline, Research Triangle Park, NC, USA
c Formerly GlaxoSmithKline, Stockley Park, London, UK
d University of Nebraska, Omaha, NE, USA
e Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and FISIB, CIBERES, Mallorca, Spain
f Respiratory Medicine, Barts and The London NHS Trust, London, UK

The authors regret that there were errors in the ‘Efficacy: co-primary’, Table 2 and Table 3 sections of the above paper. The errors are shown below.

<table>
<thead>
<tr>
<th>Location</th>
<th>Current incorrect text printed in article</th>
<th>Text should correctly read</th>
</tr>
</thead>
<tbody>
<tr>
<td>[p.563. Efficacy: co-primary section]: Furthermore, compared with FF 100 μg alone, FF/VI 100/25 μg significantly improved the adjusted mean wFEV1 at day 168 by 120 ml (95% CI: 7, 170; p &lt; 0.001) (Table 2).</td>
<td>Furthermore, compared with FF 100 μg alone, FF/VI 100/25 μg significantly improved the adjusted mean wFEV1 at day 168 by 120 ml (95% CI: 7, 170; p &lt; 0.001) (Table 2).</td>
<td></td>
</tr>
<tr>
<td>[p.566, Table 2. footnote]: CRQ-SAS dyspnoea domain is scaled from 0 to 7, with 0 indicating no impairment</td>
<td>CRQ-SAS dyspnoea domain is scaled from 1 to 7, with 1 indicating no impairment</td>
<td></td>
</tr>
<tr>
<td>[p.567, Table 3. n-value for ocular effects in FF 100 group]: 1 (&lt;=1)</td>
<td>2 (&lt;=1)</td>
<td></td>
</tr>
</tbody>
</table>

The authors apologise for any inconvenience caused.

DOI of original article: http://dx.doi.org/10.1016/j.rmed.2012.12.014.
* Corresponding author. Tel.: +1 541 858 1003.
E-mail address: ekerwin@allergyasthmaso.com (E.M. Kerwin).